StockNews.com Initiates Coverage on OpGen (NASDAQ:OPGN)

StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN – Get Rating) in a research report report published on Sunday morning. The firm issued a sell rating on the medical research company’s stock.

Other equities analysts have also issued research reports about the stock. Alliance Global Partners restated a buy rating and set a $1.25 target price on shares of OpGen in a report on Tuesday, May 31st. HC Wainwright reiterated a buy rating and issued a $3.00 price objective on shares of OpGen in a report on Friday, June 10th.

NASDAQ:OPGN opened at $0.53 on Friday. The company has a current ratio of 1.76, a quick ratio of 1.69 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $24.59 million, a price-to-earnings ratio of -0.62 and a beta of -0.53. The firm’s fifty day simple moving average is $0.50 and its 200 day simple moving average is $0.75. OpGen has a twelve month low of $0.31 and a twelve month high of $3.72.

OpGen (NASDAQ:OPGN – Get Rating) last posted its earnings results on Thursday, May 12th. The medical research company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.01. The business had revenue of $0.47 million for the quarter, compared to analyst estimates of $1.05 million. OpGen had a negative net margin of 680.36% and a negative return on equity of 72.67%. On average, analysts predict that OpGen will post -0.54 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of the business. Geode Capital Management LLC lifted its holdings in OpGen by 10.3% in the 3rd quarter. Geode Capital Management LLC now owns 353,208 shares of the medical research company’s stock worth $1,017,000 after buying an additional 32,875 shares in the last quarter. Arete Wealth Advisors LLC lifted its holdings in OpGen by 70.0% in the 1st quarter. Arete Wealth Advisors LLC now owns 85,000 shares of the medical research company’s stock worth $64,000 after buying an additional 35,000 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in OpGen by 74.6% in the 3rd quarter. Renaissance Technologies LLC now owns 151,500 shares of the medical research company’s stock worth $436,000 after buying an additional 64,747 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of OpGen in the 1st quarter valued at about $73,000. Finally, Marshall Wace LLP acquired a new stake in shares of OpGen in the 3rd quarter valued at about $744,000. Hedge funds and other institutional investors own 10.95% of the company’s stock.

About OpGen (Get Rating)

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.

Featured Stories